Analyzing the number of common integration sites of viral vectors - new methods and computer programs

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Abel, Ulrich ^a,b   Deichmann, Annette ^b   Nowrouzi, Ali ^b   Gabriel, Richard ^b   Bartholomae, Cynthia C ^b   Glimm, Hanno ^b   von Kalle, Christof ^b   Schmidt, Manfred ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ARTICLE; CLUSTER ANALYSIS; COMMON INTEGRATION SITE; COMPUTER PROGRAM; CONTROLLED STUDY; EXPERIMENTAL STUDY; GAMMA RETROVIRUS; LENTIVIRINAE; MATHEMATICAL COMPUTING; PROCESS DEVELOPMENT; RETROVIRUS; STATISTICAL MODEL; VIRUS DNA CELL DNA INTERACTION; BIOLOGICAL MODEL; COMPUTER SIMULATION; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC DATABASE; GENETICS; HUMAN; METHODOLOGY;

ANIMALIA;

COMPUTER SIMULATION; DATABASES, GENETIC; GENETIC VECTORS; HUMANS; MODELS, GENETIC; MUTAGENESIS, INSERTIONAL; RETROVIRIDAE; SOFTWARE;

EID: 80054098367     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024247     Document Type: Article

References (36)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
2. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, et al. (2002) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413.
3. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, et al. (2004) Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
4. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, et al. (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
5. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IsA, et al. (2010) Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome. New England Journal of Medicine 363: 1918-1927.
6. Du Y, Jenkins NA, Copeland NG, (2005) Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 106: 3932-3939.
7. Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, et al. (2004) Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2: e423.
8. Calmels B, Ferguson C, Laukkanen MO, Adler R, Faulhaber M, et al. (2005) Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 106: 2530-2533.
9. Kustikova O, Fehse B, Modlich U, Yang M, Dullmann J, et al. (2005) Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-1174.
10. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, et al. (2002) Murine leukemia induced by retroviral gene marking. Science 296: 497.
11. Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, et al. (2005) Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 105: 4235-4246.
12. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, et al. (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
13. Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, et al. (2007) Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117: 2225-2232.
14. Schwarzwaelder K, Howe SJ, Schmidt M, Brugman MH, Deichmann A, et al. (2007) Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 117: 2241-2249.
15. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, et al. (2008) Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
16. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, et al. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256.
17. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, et al. (2010) Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204.
18. Ott MG, Seger R, Stein S, Siler U, Hoelzer D, et al. (2007) Advances in the treatment of Chronic Granulomatous Disease by gene therapy. Curr Gene Ther 7: 155-161.
19. Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, et al. (2009) Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med 15: 1431-1436.
20. Paruzynski A, Arens A, Gabriel R, Bartholomae CC, Scholz S, et al. (2010) Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc 5: 1379-1395.
21. Schmidt M, Schwarzwaelder K, Bartholomae C, Zaoui K, Ball C, et al. (2007) High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 4: 1051-1057.
22. Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, et al. (2002) High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 32: 153-159.
23. Lund AH, Turner G, Trubetskoy A, Verhoeven E, Wientjens E, et al. (2002) Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 32: 160-165.
24. Suzuki T, Shen H, Akagi K, Morse HC, Malley JD, et al. (2002) New genes involved in cancer identified by retroviral tagging. Nat Genet 32: 166-174.
25. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, et al. (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529.
26. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, et al. (2004) Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2: E234.
27. de Ridder J, Uren A, Kool J, Reinders M, Wessels L, (2006) Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol 2: e166.
28. Starr TK, Allaei R, Silverstein KAT, Staggs RA, Sarver AL, et al. (2009) A Transposon-Based Genetic Screen in Mice Identifies Genes Altered in Colorectal Cancer. Science 323: 1747-1750.
29. Li J, Tai BC, Nott DJ, (2009) Confidence interval for the bootstrap P-value and sample size calculation of the bootstrap test. Journal of Nonparametric Statistics 21: 649-661.
30. Hsu JC, (1996) Multiple comparisons. Theory and methods. 2 ed London Chapman & Hall.
31. Abel U, Deichmann A, Bartholomae C, Schwarzwaelder K, Glimm H, et al. (2007) Real-time definition of non-randomness in the distribution of genomic events. PLoS ONE 2: e570.
32. Heuser H, (1980) Lehrbuch der Analysis, Teil 1 Stuttgart B.G.Teubner.
33. Wu X, Luke BT, Burgess SM, (2006) Redefining the common insertion site. Virology 344: 292-295.
34. Bartholomae CC, Arens A, Balaggan KS, Yanez-Munoz RJ, Montini E, et al. (2011) Lentiviral Vector Integration Profiles Differ in Rodent Postmitotic Tissues. Mol Ther 19: 703-710.
35. Barnard GA, (1947) Significance tests for 2×2 tables. Biometrika 34: 123-138.
36. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, et al. (2009) Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy. Science 326: 818-823.